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Abstract
To explore immunologic risk factors for death within 90 days of highly active antiretroviral therapy (HAART)
initiation, CD4 + and CD8 + T cell subsets were measured by flow cytometry and characterized by logistic
regression in 149 Zambian children between 9 months and 10 years of age enrolled in a prospective, observa-
tional study of the impact of HAART on measles immunity. Of 21 children who died during follow-up, 17 (81%)
had known dates of death and 16 (76%) died within 90 days of initiating HAART. Young age and low weight-
for-age z-scores were associated with increased risks of mortality within 90 days of starting HAART, whereas
CD4 + T cell percentage was not associated with mortality. After adjusting for these factors, each 10% increase in
CD8 + effector T cells increased the odds of overall mortality [OR = 1.43 (95% CI: 1.08, 1.90)] and was marginally
associated with early mortality [OR = 1.29 (95% CI: 0.97, 1.72)]. Conversely, each 10% increase in CD4 + central
memory T cells decreased the odds of overall [OR = 0.06 (95% CI: 0.01, 0.59)] and early mortality [OR = 0.09 (95%
CI: 0.01, 0.97)]. Logistic regression prediction models demonstrated areas under the receiver-operator charac-
teristic curves of ‡ 85% for early and overall mortality, with bootstrapped sensitivities of 82–85% upon vali-
dation, supporting the predictive accuracy of the models. CD4 + and CD8 + T cell subsets may be more accurate
predictors of early mortality than CD4 + T cell percentages and could be used to identify children who would
benefit from more frequent clinical monitoring after initiating HAART.
Introduction
The scale-up of highly active antiretroviral therapy(HAART) in sub-Saharan Africa has resulted in sub-
stantial reductions in mortality due to human immunodefi-
ciency virus (HIV).1 However, mortality rates of children
during the first few months of HAART remain comparable
to rates prior to HAART eligibility and approximately 10–20%
of children die within the first few months of starting
HAART.2–7 In Kenyan children, 90% of deaths occurred
within 90 days of starting HAART, and 77% of deaths in
children in the Democratic Republic of the Congo were within
60 days of starting HAART.6,8 Similarly, a recent meta-
analysis estimated that 17% of HIV-infected adults initiating
HAART in sub-Saharan Africa died within 12 months.9
Several studies assessed clinical and demographic risk
factors for mortality in HIV-infected children beginning
HAART and consistently identified low CD4 + T cell per-
centage or count, low weight-for-age z-score, young age, and
increased severity of coinfections to be associated with mor-
tality after treatment initiation.2,4,5,8,10 Only one assessed the
relationship with plasma HIV viral load and found higher
HIV viral load was associated with an increased risk of
mortality.4 T cell activation markers, particularly HLA-DR
and CD38, have been associated with HIV disease progres-
sion,11–13 but beyond CD4 + T cell levels, few reports link
specific T cell subsets with the risk of mortality.14 In addition
to depleting CD4 + T cells, HIV infection induces a chronic
state of immune activation that impairs emigration of naive
T cells from the thymus,15 increases T cell activation and
turnover,16,17 and results in increased levels of effector cells as
well as decreased proliferative and functional capacity.18,19
The objective of this study was to explore whether levels of
CD4 + and CD8 + T cell subsets were associated with an
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increased risk of mortality in HIV-infected Zambian children
beginning HAART.
Materials and Methods
Study design and population
We conducted a prospective, observational study from
January 2009 to February 2012 of HIV-infected children 9
months to 10 years of age initiating HAART at two public
clinics in Lusaka, Zambia to assess the impact of HAART on
general immune reconstitution and measles virus-specific
immunity. Enrollment occurred during a routine clinic visit
2 weeks after the initial evaluation for HAART eligibility at
the referral clinic. Children initiating HAART with a history
of prior measles vaccination were eligible for enrollment.
Follow-up study visits occurred every 3 months in concert with
routine clinical care. During the study visit, a questionnaire
was administered and a 3–5 ml peripheral blood sample was
collected. Clinical information obtained during the study visit
included height, weight, date of birth, and recent and current
illnesses. Recent illness was defined as presentation to a clinic
or hospital with an illness within 4 weeks prior to the study
visit. Current illness was defined as illness on the day of the
study visit. Underweight, stunting, and wasting were deter-
mined using the World Health Organization standards of less
than 2 standard deviations below weight-for-age (WAZ),
height-for-age (HAZ), and weight-for-height (WHZ) z-scores
from a standard reference population, respectively.20 The date
of death was ascertained by phone contact or home visit after
a child failed to return for follow-up. When the date of death
was unknown but confirmed by a parent or guardian, death
was assumed to have occurred midway between the previous
study visit and the next scheduled 3-month follow-up visit.
Laboratory assays
Blood samples arrived in the laboratory within 6 h of col-
lection and were aliquotted for hemoglobin and im-
munophenotyping. Hemoglobin was measured on a Sysmex
Kx-21 automated hematology analyzer (Sysmex Corporation,
Kobe, Japan) and reported in grams per deciliter (g/dl). Im-
munophenotyping was performed to differentiate T cell
subsets. Briefly, 50 ll of heparinized whole blood was mixed
with monoclonal antibodies against cell surface markers
(described below), red blood cells were lysed with FACSLyse
(BD Biosciences, Franklin Lakes, NJ), and cells were washed
with phosphate-buffered saline (PBS) and resuspended in 1%
paraformaldehyde.
To differentiate T cell subsets, cells were stained with
monoclonal antibodies against CD3-peridinin chlorophyll-A
protein (PerCP), CD4 or CD8 conjugated to allophycocyanin
(APC), CD45RA conjugated to fluorescein isothiocyanate
(FITC), and CCR7-phycoerythrin (PE). Total T cells were de-
fined by the expression of the pan-T cell marker CD3. To
distinguish functional T cell subsets, CD4 + and CD8 + T cells
were defined as naive (CCR7 + CD45RA + ), effector memory
(CCR7 - CD45RA - ), effector (CCR7 - CD45RA + ), and central
memory (CCR7 + CD45RA - ).21,22 Activated phenotypes were
detected using HLA-DR-FITC and CD38-PE,23 and interleu-
kin 7 receptor a (IL-7Ra) was used to detect CD8 + T cells with
the potential to develop into long-lived memory cells.24,25 All
monoclonal antibodies were obtained from BD Biosciences.
Flow cytometry data were acquired with CellQuest Pro soft-
ware (BD Biosciences) on a BD FACSCalibur flow cytometer
and immunophenotypes were analyzed using FlowJo v7.5
(Treestar, Ashland, OR). Lymphocytes were gated based on
side and forward scatter, and gating of CD4 + or CD8 + T cells
and respective subsets was determined with the use of isotype
controls.
Data analysis
Clinical and laboratory data collected at enrollment, cor-
responding to the day of HAART initiation, were used to
assess potential risk factors for mortality. Characteristics of
children were compared using Mann–Whitney U-tests for
continuous outcomes and v2 tests for binary outcomes. Age,
z-scores, hemoglobin, and cell populations were centered by
subtracting the mean value. Age was scaled by 3-month in-
tervals and cell populations were scaled by 10%. p-values less
than 0.05 were considered statistically significant.
As dates of death were unavailable for some children,
mortality was assessed as a binary outcome. Logistic regres-
sion was used to explore immunologic risk factors for overall
mortality and mortality within 90 days of HAART initiation
after adjusting for age, CD4 + T cell percentage, and WAZ as
well as to predict the probability of mortality after HAART
initiation. Given the potential collinearity between T cell
subsets, relationships between subsets not achieving statisti-
cally significant univariable associations with mortality were
assessed using correlations. Cellular subsets demonstrating
statistically significant correlations with other subsets were
selected for multivariable models. Model fit was assessed
using Hosmer–Lemeshow goodness-of-fit tests, grouping
observations into deciles.26
After identification of immunologic risk factors for mortal-
ity, concordance (C)-statistic/area under the receiver-operator
characteristic curves (AUC) were used to assess the predictive
accuracy of the logistic regression models for mortality within
90 days of HAART initiation and overall mortality. For each
model, a cut-off for the predicted probability of mortality, also
known as a criterion of positivity, was selected to categorize
children into high and low mortality risk groups. The dis-
criminatory abilities of these criteria were measured using
sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV). The criteria of positivity
maximizing sensitivity and the proportion of correctly classi-
fied individuals were selected to increase the probability of
properly differentiating children with mortality outcomes.
Discrimination measures were validated by bootstrapping
with 100 replicates.26 An additional measure of accuracy, op-
timism, which estimates the degree of model overfitting, was
calculated as the mean difference between the AUC from the
model of the observed data and the AUCs from the models of
the bootstrapped data.27 Statistical analyses were performed
using Stata/IC version 10.1 (College Park, TX).
Results
Characteristics of the study population
A total of 169 HIV-infected children were enrolled at the
time of HAART initiation in a study of the impact of HAART
on immune reconstitution and measles immunity. Children
were excluded from this analysis if the percents of CD4 + and
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CD8 + T cells were missing (n = 6), date of birth was missing
(n = 1), baseline data were unavailable (n = 3), or if children
were enrolled after November 29, 2011, which was within
3 months of the study end date of February 28, 2012, as
mortality outcomes from these children were not ascertained
(n = 11). Consequently, 149 HIV-infected children initiating
HAART were eligible for analysis and contributed 127.3
person-years (py). Children were observed for a median of
274 days (range: 1–988). One hundred and twenty-eight
children (86%) were alive at the conclusion of the study and 21
children (14%) died during follow-up. Of those who died, 16
(76%) died within 90 days of HAART initiation, four of whom
had unknown dates of death but contact tracing revealed
these children died before the first follow-up study visit 3
months after beginning HAART. Five children (24%) died
more than 90 days after starting HAART. The overall mor-
tality rate was 4.17 per 100 py (95% CI: 2.72, 6.40) and a
mortality rate of 7.95 per 100 py (95% CI: 4.87, 13.0) was ob-
served within 90 days of starting HAART, which was 4.8
times higher (95% CI: 1.7, 16.7) than that observed after 90
days of HAART [1.66 per 100 py (95% CI: 0.69, 3.99)].
The median age of children who died was younger than
survivors at the time of HAART initiation (Table 1). The me-
dian WAZ score of children who died less than 90 days after
initiating HAART was - 3.50 (IQR: - 4.34, - 2.60), significantly
lower than the WAZ score of - 2.33 (IQR: - 3.15, - 1.31) for
survivors ( p < 0.001) (Table 1). Moreover, 94% of children who
died within 90 days of HAART initiation were underweight
compared to 57% of survivors and 40% of children who died
after 90 days of HAART ( p = 0.01 by v2 test). The WHZ scores of
children who died within 90 days of HAART initiation also
were significantly lower than those of survivors. In contrast,
Table 1. Characteristics of HIV-Infected Children Who Survived or Died Within 90 Days












< 90 days, overall)
Female 61 (48%) 8 (50%) 10 (48%) 0.86, 1.00




( - 3.15, - 1.31)
- 3.50
( - 4.34, - 2.60)
- 3.28
( - 4.00, - 2.16)
< 0.01, 0.02




( - 4.16, - 1.79)
N = 124 - 3.34
( - 4.66, - 2.19)
N = 13 - 3.31
( - 4.66, - 2.19)
N = 18 0.55, 0.54




( - 1.85, 0.33)
N = 101 - 2.19
( - 3.04, - 0.73)
N = 13 - 1.46
( - 3.04, - 0.39)
0.03, 0.14
Wasting 21 (21%) N = 101 7 (54%) N = 13 8 (44%) < 0.01, 0.03
Recent illness 97 (76%) 16 (100%) 20 (95%) 0.03, 0.04
Current illness 38 (30%) 8 (50%) 11 (52%) 0.10, 0.04
Hemoglobin, g/dl 9.8 (8.8, 10.9) N = 109 9.3 (9.1, 10.2) N = 12 9.3 (9.0, 10.2) 0.34, 0.37
*p-values determined using Mann–Whitney U-tests and v2 tests.
Dichotomous characteristics are expressed as N (%) and continuous characteristics as median (interquartile range).
Table 2. T Cell Subset Percentages Among HIV-Infected Zambian Children Who Survived or Died











died <90 days, overall)
% CD4 + T cells 11.3 (7.5, 16.8) 11.6 (6.6, 15.8) 12.3 (6.7, 15.7) 0.72, 0.76
% Naive 19.6 (7.3, 35.8) 28.6 (14.4, 37.5) 28.9 (14.1, 38.4) 0.41, 0.33
% Effector 25.6 (15.7, 38.6) 35.7 (24.3, 58.5) 39.5 (25.7, 55.5) 0.04, < 0.01
% Effector memory 38.3 (25.8, 54.3) 24.4 (19.1, 38.5) 22.7 (17.7, 37.7) 0.04, < 0.01
% Central memory 4.8 (2.4, 7.6) 2.4 (1.3, 4.8) 2.3 (1.8, 4.7) 0.02, < 0.01
% Activated 11.4 (6.8, 16.3) N = 123 9.7 (7.4, 11.1) 10.4 (7.8, 11.7) 0.39, 0.56
% CD8 + T cells 43.6 (38.0, 52.4) N = 126 46.3 (32.9, 51.8) 48.1 (38.3, 53.6) 0.90, 0.56
% Naive 3.2 (1.2, 7.1) N = 126 3.3 (1.9, 6.2) 3.4 (1.9, 6.5) 0.72, 0.60
% Effector 50.2 (37.0, 64.0) N = 126 70.0 (51.7, 75.8) 68.9 (53.9, 76.8) < 0.01, < 0.01
% Effector memory 41.2 (28.6, 57.4) N = 126 26.0 (21.7, 39.3) 25.2 (19.3, 40.3) 0.01, < 0.01
% Central memory 0.08 (0.03, 0.19) N = 126 0.03 (0.00, 0.11) 0.04 (0.02, 0.09) 0.08, 0.06
% Activated 34.4 (20.8, 45.4) N = 126 30.1 (24.2, 47.9) 30.7 (25.1, 47.4) 0.94, 0.89
% IL-7Ra 10.4 (4.4, 16.8) N = 125 10.9 (5.2, 15.7) 9.7 (6.2, 14.9) 0.75, 0.80
*p-values determined using Mann–Whitney U-tests.
Subsets of CD4 + or CD8 + T cells are presented as median (interquartile range) and defined as naive: CCR7 + CD45RA + , effector memory:
CCR7 - CD45RA - , effector: CCR7 - CD45RA + , central memory: CCR7 + CD45RA - , and activated: HLA-DR + CD38 + .
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the median HAZ scores were less than zero for all groups but
did not differ significantly between groups (Table 1).
Hemoglobin concentrations and the proportion of mothers
receiving perinatal antiretroviral therapy did not differ be-
tween children who died and survivors. All children who
died within 90 days of beginning HAART had a recent illness
and half were ill on the day of HAART initiation; in contrast,
76% and 30% of survivors were recently and currently ill
( p = 0.08 and p = 0.11, respectively). Nineteen (90%) of the 21
children who died had more than one symptom of illness.
Signs and symptoms consisted of cough (n = 18), diarrhea
(n = 18), fever (n = 16), sore throat (n = 8), vomiting (n = 8), ear
discharge (n = 5), and rash (n = 5). Children were receiving
cotrimoxazole prophylaxis.
The percentages of CD4 + T cells did not differ between
children who died and those who survived with medians of
11.3% (IQR: 7.5%, 16.8%) and 12.3% (IQR: 6.7%, 15.7%),
respectively ( p = 0.72 and 0.76 by Mann–Whitney U-test) (Table
2). Activated T cells, defined by the expression of CD38 and
HLA-DR, also did not differ between survivors and children
who died. In contrast, CD4 + effector and CD8 +effector T cell
percentages were ‡ 13.9% higher among those who died
(all p-values £ 0.04) (Fig. 1), whereas effector memory T cell
percentages for both CD4 + and CD8+ T cell populations
were ‡ 10.1% lower among children who died (all p-values
£ 0.04) (Fig. 2). CD4 + and CD8+ central memory T cells were 2-
fold higher in survivors compared to children who died within
90 days of HAART initiation ( p = 0.02 and 0.08) (Fig. 3).
Associations between subsets were assessed using correla-
tions to reduce the potential for including collinear subsets
in multivariable models. Percentages of CD4+ T cells were
marginally correlated with CD4+ effector memory T cell
percentages (q = - 0.16, p = 0.05) and CD4+ effector T cell
percentages (q = 0.14, p = 0.09) (Supplementary Fig. S1; Sup-
plementary Data are available online at www.liebertpub
.com/aid). CD8+ effector T cells were strongly correlated with
CD4+ effector and CD4+ effector memory T cell percentages
(q = 0.56 and - 0.64, both p < 0.001) as well as CD8+ effector
memory and CD8+ central memory T cell percentages (q =
- 0.79 and - 0.34, p < 0.001), but not with total CD4+ or CD4+
central memory T cell percentages. Therefore, total CD4+ ,
CD8+ effector, and CD4+ central memory T cell percentages
were included in the multivariable models.
Risk of overall mortality after initiating HAART
Risk factors for overall mortality and mortality within
90 days of beginning HAART were assessed separately. In
univariable analysis, each 3-month increase in age and 1-unit
increase in WAZ score were associated with 12% (95% CI: 2,
20) and 32% (95% CI: 4, 53) decreased risks of mortality, re-
spectively, while total CD4 + T cell percentage was not asso-
ciated with the risk of overall mortality [univariable OR: 0.82
(95% CI: 0.40, 1.65)] (Table 3). Increases in the percentages of
CD4 + effector and CD8 + effector T cells were associated with
a 1.47-fold (95% CI: 1.14, 1.90) and 1.59-fold (95% CI: 1.17,
2.16) increased odds of overall mortality, while increased
percentages of CD4 + effector memory and central memory
T cells decreased the risk of overall mortality (Table 3). After
adjusting for age, WAZ score, and CD4 + T cell percentage,
10% increases in CD8 + effector and CD4 + central memory
T cells remained independently associated with overall mor-
tality, producing 1.43-fold (95% CI: 1.08, 1.90) and 0.06-fold
(95% CI: 0.01, 0.59) changes in the odds of mortality after
HAART initiation (Table 3).
Risk of mortality within 90 days of initiating HAART
Similar associations were observed between T cell subsets
and mortality within 90 days of HAART initiation. Increased
age and WAZ score were associated with decreased risks of
mortality within 90 days of HAART initiation in univariable































































FIG. 1. (a) CD4 + effector T cells and (b) CD8 + effector T
cells among HIV-infected Zambian children who survived
and died less than or greater than 90 days after beginning
highly active antiretroviral therapy.
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with mortality (Table 3). Ten percent increases in CD4 + ef-
fector and CD8 + effector T cells were associated with 1.31-fold
(95% CI: 0.99, 1.73) and 1.43-fold (95% CI: 1.04, 1.96) increased
odds of death within 90 days of beginning HAART (Table 3).
The point estimates for both CD4 + memory populations were
consistent with those observed with overall mortality, al-
though only that for central memory cells was statistically
significant. Adjusting for age, WAZ score, and CD4 + T cell
percentage attenuated the association between early mortality
and CD8 + effector T cell percentage [odds ratio (OR): 1.29
(95% CI: 0.97, 1.72)], while an increased percentage of CD4 +
central memory T cells remained negatively associated with
the risk of death [OR: 0.09 (95% CI: 0.01, 0.97)] (Table 3).
Discriminatory characteristics of models for mortality
We assessed the ability of the multivariable models to
distinguish children who died from those who survived. For
the models of overall mortality and mortality within 90 days
of HAART initiation, inclusion of both CD8 + effector T cells
and CD4 + central memory T cells after adjusting for age,
WAZ score, and CD4 + T cell percentage produced the highest
bootstrapped AUC values of 85.4% and 85.3%, respectively.
The optimism, or estimate of model overfitting, was 4.5% for
the model of mortality within 90 days of HAART initiation
and 3.8% for the overall mortality model, producing corrected
AUC values of 80.8% and 81.6%.
Each point on the receiver-operator characteristic curves
represents the predicted probability of mortality from a lo-
gistic regression model (similar to a continuous result from a
screening or diagnostic test) and choosing a cut-off among
these probabilities makes it possible to categorize children
into groups of high and low mortality risk. The cut-off or
‘‘criterion of positivity’’ was selected from these probabilities
to calculate measures of model discrimination that maxi-
mized sensitivity and the proportion of correctly classified
children. A criterion of positivity of 0.09 (i.e., the probability of
mortality) for the model of overall mortality properly classi-
fied mortality outcomes for 66.7% of children and resulted in a
sensitivity of 90.5% (Fig. 4a). Moreover, a predicted proba-























































FIG. 2. (a) CD4 + effector memory T cells and (b) CD8 +
effector memory T cells among HIV-infected Zambian chil-
dren who survived and died less than or greater than 90 days


























FIG. 3. CD4 + central memory T cell subsets among HIV-
infected Zambian children who survived and died less than
or greater than 90 days after beginning highly active anti-
retroviral therapy.
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negative predictive value of 97.5% (79 of 81 children alive
with a predicted probability of less than 9%). Thus, a majority
of children at low risk of mortality outcomes were properly
classified using this model. For mortality within 90 days of
HAART initiation, a criterion of positivity of 0.11 captured the
highest number of children who had post-HAART mortality
outcomes with a sensitivity of 81.3%, while simultaneously
misclassifying the fewest number of children (Fig. 4b).
Discussion
Mortality was high within the first 3 months of starting
HAART in this cohort of HIV-infected children receiving care
in urban Zambia. Previously identified risk factors for mor-
tality among children initiating HAART, including younger
age and undernutrition, were associated with mortality;
however, anemia and immune suppression, as measured by
CD4 + T cell percentage, were not associated with mortality.
This may have been due in part to the younger age of this
cohort in comparison with other studies.5 Importantly, chil-
dren with a higher percentage of CD8 + effector T cells and
those with a lower percentage of CD4 + central memory T cells
were at increased risk of mortality. These T cell subsets may
better reflect immunologic dysfunction than total CD4 + T cell
percentage.
Effective immune responses are critical for protection
against opportunistic infections and other HIV-related
illnesses, and require virologic suppression and immune
reconstitution with HAART. Consistent with previous re-
ports, approximately 75% of the mortality observed in this
cohort occurred within 90 days of HAART initiation.6,8 The
overall and early mortality rates of 4.17 and 7.95 deaths per
100 py observed in this cohort were lower than rates observed
in other studies of children receiving HAART in sub-Saharan
Africa.3–6,8,28 A mortality rate of 17.4 deaths per 100 py was
observed within the first 90 days of HAART in a large study of
Zambian children in urban Lusaka.5 Within 4 months of be-
ginning HAART, Kenyan children died at the strikingly high
rate of 46 deaths per 100 py.6 These early deaths may reflect
late clinical presentation, advanced immunosuppression,
and severe opportunistic infections, as well as the inability of
HAART to rapidly reverse immunologic damage caused by
HIV infection.
Among healthy individuals, naive T cells are activated
following antigen exposure and differentiate into memory
and effector cells. Effector T cells induce cytolysis of infected
cells or activate other lymphocytes and immune effector cells,
whereas memory T cells maintain the capacity to respond
rapidly to previously encountered antigens. We found no
differences in the percentages of CD8 + naive T cells between
children who died and survived. However, children who died
had 20% higher CD8 + effector T cell percentages and half the
CD4 + central memory T cell percentages of survivors, sug-
gesting altered differentiation pathways in children who died.
Table 3. Clinical and Immunological Risk Factors for Overall Mortality and Mortality Within 90 Days
of Initiating Highly Active Antiretroviral Therapy
Death during follow-up Death within 90 days
Univariable
Multivariable
OR (95% CI) Univariable
Multivariable
OR (95% CI)
OR (95% CI) N N = 147 OR (95% CI) N N = 147
3-month increase in age 0.88 (0.80, 0.98) 0.86 (0.77, 0.98) 0.89 (0.79, 0.99) 0.87 (0.76, 1.00)
Weight-for-age z-score 0.68 (0.47, 0.96) 0.69 (0.48, 1.00) 0.53 (0.35, 0.82) 0.54 (0.34, 0.86)
Height-for-age z-score 0.91 (0.71, 1.17) 142 0.91 (0.68, 1.22) 142
Weight for-height z-score 0.86 (0.66, 1.10) 119 0.76 (0.56, 1.01) 119
Hemoglobin (g/dl) 0.91 (0.71, 1.17) 126 0.91 (0.69, 1.22) 126
Recent illness 6.39 (0.82, 49.6) —*
Current illness 2.61 (1.02, 6.65) 2.24 (0.79, 6.39)
10% increase in
% CD4 + T cells 0.82 (0.40, 1.65) 0.69 (0.22, 1.46) 0.84 (0.38, 1.86) 0.59 (0.21, 1.67)
% Naive 1.08 (0.85, 1.37) 1.07 (0.81, 1.40)
% Effector 1.47 (1.14, 1.90) 1.31 (0.99, 1.73)
% Effector memory 0.73 (0.56, 0.95) 0.82 (0.63, 1.06)
% Central memory 0.10 (0.02, 0.64) 0.06 (0.01, 0.59) 0.13 (0.02, 0.99) 0.09 (0.01, 0.97)
% Activated 0.82 (0.46, 1.46) 144 0.80 (0.40, 1.57) 144
% CD38 + 1.10 (0.81, 1.51) 144 0.80 (0.40, 1.57) 144
% HLA-DR + 0.86 (0.54, 1.38) 144 1.00 (0.73, 1.36) 144
% CD8 + T cells 1.00 (0.68, 1.44) 147 0.84 (0.57, 1.25) 147
% Naive 0.86 (0.41, 1.80) 147 0.80 (0.32, 1.98) 147
% Effector 1.59 (1.17, 2.16) 147 1.43 (1.08, 1.90) 1.43 (1.04, 1.96) 147 1.29 (0.97, 1.72)
% Effector memory 0.69 (0.52, 0.92) 147 0.76 (0.57, 1.02) 147
% Central memory 0.09 ( < 0.01, 5103) 147 0.19 ( < 0.01, 1328) 147
% Activated 1.01 (0.77, 1.32) 147 1.01 (0.75, 1.37) 147
% CD38 + 1.22 (0.84, 1.76) 147 1.12 (0.79, 1.60) 147
% HLA-DR + 0.96 (0.75, 1.24) 147 0.97 (0.73, 1.29) 147
% IL-7Ra 1.03 (0.76, 1.40) 146 1.07 (0.77, 1.48) 146
*All children who died within 90 days of HAART initiation were recently ill.
N = 149 children unless otherwise noted; OR = odds ratio; g/dl = grams per deciliter.
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Elevated levels of HIV-specific and other pathogen-specific
effector T cells have been observed in persons with chronic
HIV infection,29–32 and may reflect immune exhaustion, a
state characterized by the loss of cytokine production, cyto-
toxicity, and proliferation after continual antigen stimula-
tion.33,34 Conversely, central memory T cells are frequently
lower in HIV-infected individuals regardless of treatment
status but are necessary for long-term protective immune
responses.19,35 This combination of immunophenotypes
suggests children who died were unable to mount effective
immune responses to coinfecting pathogens.
We attempted to identify thresholds of effector and mem-
ory T cell percentages that could aid in differentiating mor-
tality risk but found these had poor discriminatory ability.
Additionally, this approach neglected to account for con-
founding by age, nutritional status, and disease status. Sub-
stantial maturational changes occur in the composition of
T cell subsets in younger children, making summary mea-
sures potentially misleading among children spanning a
broad age range. Therefore, models were developed to adjust
for these factors as well as allow for the contribution of mul-
tiple cellular subsets to mortality risk. After adjusting for age,
WAZ score, and CD4 + T cell percentage, associations be-
tween mortality and effector and central memory T cells re-
mained. Importantly, total CD4 + T cell percentage at the time
of starting HAART was not associated with mortality in this
cohort. After compensating for model overfitting, the AUC
values suggested these models provided good measures of
discrimination within this cohort, although the ability of
CD4 + central memory T cells and CD8 + effector T cells to
predict mortality should be confirmed in larger studies as the
small number of deaths limited statistical power.
The process of immune reconstitution following HAART
can unmask underlying illnesses and result in paradoxical
exacerbation of opportunistic illnesses such as tuberculosis
and contribute to immune reconstitution inflammatory syn-
drome (IRIS).36,37 Associations between increased CD8+ ef-
fector T cell percentages at HAART initiation and both overall
and early mortality may signal unrecognized, severe oppor-
tunistic infections or higher levels of HIV-specific effector cells
corresponding to higher viral loads.29 IRIS may have con-
tributed to some of the deaths observed in this cohort but
causes of death were not ascertained. The lack of HIV viral
load data was a limitation, although only one prior study
found that a plasma HIV viral load of > 750,000 copies/ml was
associated with mortality in univariate analysis but not after
adjustment for CD4+ T cell percentage, age, and WAZ score.4
The inclusion criteria limit the generalizability of study
findings to children older than 9 months of age accessing
medical care. By requiring evidence of prior measles vacci-
nation on an Under-5 Immunization Card, this study may
have excluded children with poorer access to care and po-
tentially more advanced immunosuppression; however,
medical care is free at the clinics where enrollment occurred.
The cellular subsets associated with early mortality after
HAART initiation may provide insight into the mechanisms
contributing to immunological dysfunction, impaired im-
mune reconstitution, and preventable mortality. Further re-
search linking changes in specific cellular subsets with clinical
markers and specific disease conditions may aid in identifying
HIV-infected children who would benefit from starting
HAART earlier than current guidelines suggest or the need for
more frequent clinical monitoring after starting HAART.
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ation included covariates for CD4 + central memory T cell
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cell percentage, weight-for-age z-score, and 3-month in-
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